Terns Pharmaceuticals, Inc.
TERN
주식 순위
#3572
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
주가
$52.95
마지막 동기화: 2026-05-15
시가총액
$4.77B
변동 (1일)
0.00%
변동 (1년)
529.61%
국가
US
거래 Terns Pharmaceuticals, Inc. (TERN)
카테고리
Healthcare
Terns Pharmaceuticals, Inc. (TERN)의 발행 주식 수
December 2025 기준 발행 주식 수: 93.17M
Terns Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 93.17M입니다. December 2023 말 기준 회사는 71.26M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Terns Pharmaceuticals, Inc. (TERN)의 발행 주식 수 기록 (2018 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 93.17M | 17.18% |
| 2024 | 79.51M | 11.57% |
| 2023 | 71.26M | 97.76% |
| 2022 | 36.03M | 42.60% |
| 2021 | 25.27M | 0.57% |
| 2020 | 25.13M | 0.11% |
| 2019 | 25.10M | 4.69% |
| 2018 | 23.97M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| 253.90M | 172.52% |
US
|
|
| 396.00M | 325.05% |
US
|
|
| 478.91M | 414.04% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -33.25% |
NL
|
